Complex Biologics CDMO+ CRO - Abzena

Episcreen® 2.0 Cytokine Screen™

Discover EpiScreen®2.0

The Episcreen® 2.0 Cytokine Screen™ assay evaluates the potential of therapeutic proteins to activate innate and adaptive immune responses resulting in rapid and excessive cytokine release, which can produce significant toxicity.

Elevated cytokine levels are measurable in the serum of patients within minutes to hours after infusion. In vitro and in vivo animal studies have failed to be predictive of such severe reactions, as evident in the TGN1412 clinical trial (Suntharalingam et al, 2006).

Contact Us

Cytokine Screen™

Abzena have developed an enhanced in vitro assay, Cytokine Screen™, to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to clinical trials.

Available as whole blood to assess innate responses or PBMC format to study adaptive responses with standard or bespoke cytokine panels.

Contact Us

Abzena’s immunogenicity assay services are tailored to each project. This ensures that your goals are met or exceeded. Our experienced project teams are assigned to each study focusing on progressing projects through to results.

Contact Us

Related Resources & Insights

Immunogenicity Assays

An integral service to biologic drug development. Immunogenicity assays help you better understand your drug earlier, allowing you to start smart, and finish fast.

Learn More

Abzena Launches EpiScreen® 2.0 Immunogenicity Platform

Learn More

Blog: Immunogenicity Assessments – Frequently Asked Questions

Discover our blog of frequently asked questions on immunogenicity assays and addressing the complexities of immunogenicity in biologic therapies.

Learn More

EpiScreen® 2.0 DC:T Cell Assay

Assessing antibody immunogenicity and the 'adjuvant effect' of different product formulations on immunogenicity.

Learn More

EpiScreen® 2.0 MAPPs: MHC Class II Associated Peptide Proteomics

Identifying MHC Class II bound peptides processed and presented by dendritic cells (DCs) from therapeutic proteins/mAbs.

Learn More

EpiScreen® 2.0 T Cell Epitope Mapping

Identifying CD4+ T cell epitopes within protein sequences in order to design deimmunized variants.

Learn More

EpiScreen® 2.0 Time Course T Cell Assay

These assays have been used extensively as a standard for preclinical immunogenicity testing.

Learn More

EpiScreen® 2.0: Smarter Immunogenicity Testing

A comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Learn More